This announcement is worth a read again. Follow the science. Results presented here that no other pharma company persuing DMD have ever come close to achieving.
Ann: Trial Met Primary & Exceeded Secondary Endpoint Expectations, page-222
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.001(1.32%) |
Mkt cap ! $68.51M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.7¢ | 7.6¢ | $18.83K | 247.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13033 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 191003 | 2 |
View Market Depth
| Last trade - 13.53pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
0.001 ( 3.80 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.6¢ | 7.6¢ | 54789 | ||
| Last updated 11.44am 21/05/2024 ? | |||||
| PER (ASX) Chart |